Editorial

Reducing refractory angina

EuroIntervention 2021;16:e1466-e1467. DOI: 10.4244/EIJV16I18A265

Ranil de Silva
Ranil de Silva1,2, PhD, FRCP; Kevin Cheng1,2, MA, BMBCh, MRCP
1. National Heart and Lung Institute, Imperial College London, London, United Kingdom; 2. Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
Cardiologists increasingly face the challenges of managing patients with refractory angina (RA) in their clinical practice. The prevalence of RA is increasing with few therapies shown to improve symptoms and quality of life in appropriately powered randomised controlled trials1. Patients with RA have significant morbidity and their management incurs significantly increased healthcare costs2. The coronary sinus Reducer™ (CSR; Neovasc Inc., Richmond, BC, Canada), a stainless steel hourglass-shaped device which is inserted transvenously into the coronary sinus, has been shown, in a randomised sham-procedure controlled trial in patients with RA, to improve Canadian Cardiovascular Society (CCS) angina class and exercise ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Similar long-term outcome of dissimilar drug-eluting stents: is it time to change the assessment?

Latest news